Novel anti-inflammatory interleukin-35 as an emerging target for anti-atherosclerotic therapy

Current Pharmaceutical Design

Volumn 21, Issue 9, 2015, Pages 1147-1151

  Bobryshev, Yuri V ^a,b   Sobenin, Igor A ^c,d   Orekhov, Alexander N ^c,e   Chistiakov, Dimitry A ^f  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

^c INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^d INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^e Institute for Atherosclerosis Research   (Russian Federation)

^f PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Anti atherosclerotic therapy; Arteries; Atherogenesis; Atherosclerosis; Inflammation; Interleukin 35

Indexed keywords

ANTIBODY; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 35; INTERLEUKIN RECEPTOR; AUTACOID; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, HUMAN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; DRUG TARGETING; HUMAN; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REGULATORY T LYMPHOCYTE; TH17 CELL; VASCULITIS; BIOLOGICAL MODEL; BIOSYNTHESIS; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; SIGNAL TRANSDUCTION;

ATHEROSCLEROSIS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-12 RECEPTOR BETA 2 SUBUNIT; INTERLEUKINS; MODELS, IMMUNOLOGICAL; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 84925854057     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666141014123810     Document Type: Article

References (54)

1. Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of regulatory T cells. Immunity 2013; 38: 4414-23.
2. Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol 2006; 1: 297-329.
3. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 2045-51.
4. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Cytokine network and T cell immunity in atherosclerosis. Semin Immunopathol 2009; 31: 23-33.
5. Sasaki N, Yamashita T, Takeda M, Hirata K. Regulatory T cells in atherogenesis. J Atheroscler Thromb 2012; 19: 503-15.
6. Chistiakov DA, Sobenin AN, Orekhov AN. Regulatory T cells in atherosclerosis and strategies to induce the endogenous atheroprotective immune response. Immunol Lett 2013; 151: 10-22.
7. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566-9.
8. Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DA. Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 2011; 186: 6661-6.
9. Castellani ML, Anogeianaki A, Felaco P, et al. IL-35, an antiinflammatory cytokine which expands CD4+CD25+ Treg cells. J Biol Regul Homeost Agents 2010; 24: 131-5.
10. Collison LW, Chaturvedi V, Henderson AL, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010; 11: 1093-101.
11. Li X, Mai J, Virtue A, et al. IL-35 is a novel responsive antiinflammatory cytokine-a new system of categorizing antiinflammatory cytokines. PLoS One 2012; 7: e33628.
12. Niedbala W, Wei XQ, Cai B, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17cells. Eur J Immunol 2007; 37 :3021-9.
13. Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 2010; 184: 7144-53.
14. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566-9.
15. Whitehead GS, Wilson RH, Nakano K, Burch LH, Nakano H, Cook DN. IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. J Allergy Clin Immunol 2012; 129: 207-15: e1-5.
16. Huang Y, Lin YZ, Shi Y, Ji QW. IL-35: a potential target for the treatment of atherosclerosis. Pharmazie 2013 ;68: 793-5.
17. Collison LW, Vignali DA. Interleukin-35: odd one out or part of the family? Immunol Rev 2008; 226: 248-62.
18. Bardel E, Larousserie F, Charlot-Rabiega P, Coulomb-L’Hermine A, Devergne O. Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J Immunol 2008; 181: 6898-905.
19. Homma Y, Cao S, Shi X, Ma X. The Th2 transcription factor c-Maf inhibits IL-12p35 gene expression in activated macrophages by targeting NFkappaB nuclear translocation. J Interferon Cytokine Res 2007; 27: 799-808.
20. Poleganov MA, Bachmann M, Pfeilschifter J, Muhl H. Genomewide analysis displays marked induction of EBI3/IL-27B in IL-18-activated AML-derived KG1 cells: critical role of two kappaB binding sites in the human EBI3 promoter. Mol Immunol 2008; 45: 2869-80.
21. Pflanz S, Timans JC, Cheung J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002; 16: 779-90.
22. Rual JF, Venkatesan K, Hao T, et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature 2005; 437: 1173-8.
23. Devergne O, Hummel M, Koeppen H, et al. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol 1996; 70: 1143-53.
24. Gallagher WM, Bergin OE, Rafferty M, et al. Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis 2005; 26: 1856-67.
25. Szyf M. Epigenetic therapeutics in autoimmune disease. Clin Rev Allergy Immunol 2010; 39: 62-77.
26. Kim YJ, Park SW, Kim TH, et al. Genome-wide methylation profiling of the bronchial mucosa of asthmatics: relationship to atopy. BMC Med Genet 2013; 14: 39.
27. Lawrence de Koning AB, Werstucka GH, Zhoua J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem 2003; 36: 431-41.
28. Zaina S, Wickström Lindholm M, Lund G. Nutrition and aberrant DNA methylation patterns in atherosclerosis: more than just hyperhomocysteinemia. J Nutr 2005; 135: 5-8.
29. Chen WJ, Yin K, Zhao GJ, Fu YC, Tang CK. The magic and mystery of microRNA-27 in atherosclerosis. Atherosclerosis 2012; 222: 314-23.
30. Yang M, Liu W, Pellicane C, et al. Identification of miR-185 as a regulator of de novo cholesterol biosynthesis and low density lipoprotein uptake. J Lipid Res 2014; 55: 226-38.
31. Neth P, Nazari-Jahantigh M, Schober A, Weber C. MicroRNAs in flow-dependent vascular remodeling. Cardiovasc Res 2013; 99: 294-303.
32. Jones LL, Vignali DAA. Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily. Immunol Res 2011; 51: 5-14.
33. Kim Y, Sung JY, Ceglia I, et al. Phosphorylation of WAVE1 regulates actin polymerization and dendritic spine morphology. Nature 2006; 442: 814-7.
34. Kubin M, Kamoun M, Trinchieri G. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med 1994; 180: 211-22.
35. Jalonen U, Nieminen R, Vuolteenaho K, Kankaanranta H, Moilanen E. Down-regulation of tristetraprolin expression results in enhanced IL-12 and MIP-2 production and reduced MIP-3alpha synthesis in activated macrophages. Mediators Inflamm 2006; 2006: 40691.
36. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 2008; 79: 581-8.
37. Collison LW, Delgoffe GM, Guy CS, et al. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 2012; 13: 290-9.
38. Chua AO, Wilkinson VL, Presky DH, Gubler U. Cloning and characterization of a mouse IL-12 receptor-beta component. J Immunol 1995; 155: 4286-94.
39. Presky DH, Yang H, Minetti LJ, et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci USA 1996; 93: 14002-7.
40. Andersson J, Tran DQ, Pesu M, et al. CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta dependent manner. J Exp Med 2008; 205: 1975-81.
41. Takeda A, Hamano S, Yamanaka A, et al. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol 2003; 170: 4886-90.
42. Pflanz S, Hibbert L, Mattson J, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004; 172: 2225-31.
43. Silver JS, Hunter CA. gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol 2010; 88: 1145-56.
44. Villarino A, Hibbert L, Lieberman L, et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 2003; 19: 645-55.
45. Hibbert L, Pflanz S, de Waal Malefyt R, Kastelein RA. IL-27 and IFN-α signal via Stat1 and Stat3 and induce T-Bet and IL-12Rβ2 in naïve T cells. J Interferon Cytokine Res 2003; 23: 513-22.
46. Bacon CM, Petricoin EF 3rd, Ortaldo JR, et al. Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in/human lymphocytes. Proc Natl Acad Sci USA 1995; 92: 7307-11.
47. Collison LW, Pillai MR, Chaturvedi V, Vignali DA. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35-and IL-10-dependent manner. J Immunol 2009; 182: 6121-8.
48. Kempe S, Heinz P, Kokai E, Devergne O, Marx N, Wirth T. Epstein-Barr virus-induced gene-3 is expressed in human atheroma plaques. Am J Pathol 2009; 175: 440-7.
49. Lin Y, Huang Y, Lu Z, et al. Decreased plasma IL-35 levels are related to the left ventricular ejection fraction in coronary artery diseases. PLoS One 2012; 7: e52490.
50. Wang B, Dai S, Dong Z, et al. The modulation of endoplasmic reticulum stress by chemical chaperone upregulates immune negative cytokine IL-35 in apolipoprotein E-deficient mice. PLoS One 2014; 9: e87787.
51. McAlpine CS, Werstuck GH. The development and progression of atherosclerosis: evidence supporting a role for endoplasmic reticulum (ER) stress signaling. Cardiovasc Hematol Dis Drug Targets 2013; 13: 158-64.
52. Zeng W, Guo YH, Qi W, et al. 4-phenylbutiric acid suppresses inflammation through regulation of endoplasmic reticulum stress of endothelial cells stimulated by uremic serum. Life Sci 2014; 103: 15-24.
53. Wang RX, Yu CR, Dambuza IM, et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med 2014; 20: 633-41.
54. Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014; 507: 366-70.